Equity Analyst, LightStream Research

Shifara Samsudeen, ACMA, CGMA

Equity Analyst

Long-Short Analysis on Japan, Asia and the World

LightStream Research

LightStream conducts quantitatively rigorous and data-driven analysis with a focus on Japan and Asia.

We consistently cover the Tech, Consumer and Industrial sectors, and provide ECM and Events coverage more broadly.

We supplement traditional qualitative insights from company relationships with a robust quantitative foundation that examines as much historical data as is available.
We further refine the accuracy of our insights and calls through the use of alternative data to flesh out current trends, and through a valuation framework that emphasises non-superficial peer group selection and a proper attempt to understand the metrics and changes that have driven security valuations in the past.

Event-Driven

<ul>
<li>AGC, the Japanese manufacturer of glass, electronics, chemicals and ceramics announced on Tuesday (17<sup>th</sup> March) that it has launched a voluntary tender offer to buy all of the ordinary shares of Molecular Medicine S.p.A. (Molmed).</li>
<li>Molmed is a clinical stage biotechnology company engaged in the research and development of gene and cell therapies and also offers GMP services for the development and manufacturing of gene &amp; cell therapies for third parties and/or in partnership at its authorized facilities.</li>
<li>AGC has offered to buy Molmed’s shares at EUR0.518 per share which values the offer at EUR240m. Molmed’s shares closed at EUR0.26 per share at the close of Monday’s trading, and the offer implies a 100% premium on the biotech company’s last closed price.</li>
</ul>


AGC, the Japanese manufacturer of glass, electronics, chemicals and ceramics announced on Tuesday (17th March) that it has launched a voluntary tender offer to buy all of the ordinary shares of Molecular Medicine S.p.A. (Molmed).
Molmed is a clinical stage biotechnology company engaged in the research and development of gene and cell therapies and also offers GMP services for the development and manufacturing of gene &amp; cell therapies for third parties and/or in partnership at its authorized facilities.
AGC has offered to buy Molmed’s shares at EUR0.518 per share which values the offer at EUR240m. Molmed’s shares closed at EUR0.26 per share at the close of Monday’s trading, and the offer implies a 100% premium on the biotech company’s last closed price.


Japan’s AGC Launches Voluntary Tender Offer on Italian Biotech Firm Molmed

Italy

Molecular Medicine SpA (MolMed) is a medical biotechnology company.  The Company is focused on discovery, R&D, and clinical validation of innovative therapies for the treatment of cancer.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Molecular Medicine SPA (MLM IM)

Japan’s AGC Launches Voluntary Tender Offer on Italian Biotech Firm Molmed

AGC, the Japanese manufacturer of glass, electronics, chemicals and ceramics announced on Tuesday (17th March) that it has launched a voluntary...

Shifara Samsudeen, ACMA, CGMA

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)